Open AccessNaturally Occurring Resistance Associated Substitutions in Non-Cirrhotic, Treatment Naive HCV–HIV Co-Infected Patients Does Not Affect the Treatment Response for Anti-HCV Antiviral Therapy
Author(s) -
Ekta Gupta,
Reshu Agarwal,
Aayushi Rastogi,
Nitiksha Rani,
Ankur Jindal
Publication year - 2021
Publication title -
infection and drug resistance
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.033
H-Index - 39
ISSN - 1178-6973
DOI - 10.2147/idr.s301032
Subject(s) - sofosbuvir , medicine , daclatasvir , ns5a , hepatitis c virus , gastroenterology , ribavirin , combination therapy , univariate analysis , drug resistance , virology , hepacivirus , virus , multivariate analysis , biology , microbiology and biotechnology
Limited literature on the prevalence of baseline resistance associated substitutions (BL-RAS) among HCV-HIV co-infected patients and their association with treatment outcomes is available especially from India. Hence, the present study aimed to study naturally occurring RAS among non-cirrhotic HCV-HIV co-infected patients and their impact on the response to anti-HCV therapy.